drugset / Trial / NCT00122447
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Completed
84 enrolled
Emory University
Daiichi Sankyo · collabNational Center for Research Resources (NCRR) · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
Timeline
- Start
- 2005-05
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 325 mg | Oral |
| Comparator | Olmesartan | Other / unclassified | 40 mg | Oral |
| Comparator | alpha-lipoic acid | Small molecule | 600 mg | Oral |